Our proposed mechanism (Fig. 4) on the beneficial effects of increased hepatic CAV‐1 on protection against atherosclerosis in DKO mice remains to be verified in humans with reduced CYP27A1 activity. This evidence concerns the gene CAV1 and atherosclerosis.